Academician of the Chinese Academy of Engineering, chief physician, professor, and doctoral supervisor. He is currently the director of the Neurosurgery Center of Beijing Tiantan Hospital affiliated to Capital Medical University, the director of Beijing Neurosurgery Institute, the vice president of the School of Neurosurgery of Capital Medical University, and the deputy director of the National Center for Neurological Diseases. He is the first chairman of the Glioma Professional Committee of the Chinese Medical Doctor Association and the Chinese Anti-Cancer Association. He is currently the president of the Beijing Medical Science and Health Society, the chairman of the Asian Glioma Genome Atlas Project, and the Chinese chairman of the Global Glioma Clinical Trial Project. Editor-in-chief of "Neurological Diseases and Mental Health", deputy editor-in-chief of "Journal of Clinical Surgery", deputy editor-in-chief of "Chinese Clinical Practical Medicine", and deputy editor-in-chief of "Cancer Biology & Medicine".

He has been engaged in medical, teaching and research work in the field of comprehensive treatment of brain tumors for a long time. He has built the world's largest multidimensional genomics database of brain gliomas, leading the world's individualized diagnosis and treatment of gliomas based on molecular pathology. He took the lead in conducting molecular pathology research on gliomas in China and introduced molecular typing into glioma classification before WHO. He discovered the fusion gene PTPRZ1-MET that promotes the malignant progression and drug resistance of gliomas, and developed the original targeted drug PLB-1001. The results were published in Cell and won the Top Ten Advances in Chinese Life Sciences in 2018. He took the lead in carrying out awakening surgery in China and established a technical system for motor area protection; established a multilingual language area precision positioning protection plan, and created a staged resection procedure for gliomas in the language function area, with significantly better results than international reports. He has published 362 papers and 10 cover papers in high-level journals such as Cell and PNAS as the corresponding author; he has been cited 15,700 times and has an H index of 66. There are 23 papers in the top 1% of highly cited papers, 46 of which are included in domestic and foreign guidelines, and 20 are cited by international policy documents. He presided over the formulation of multiple diagnosis and treatment guidelines and specifications such as the "Diagnosis and Treatment Specifications for Brain Glioma" and "Diagnosis and Treatment Guidelines for Brain Glioma" of the National Health Commission, and edited a unified textbook. He has obtained 1 Class III medical device registration certificate and 25 domestic and foreign patents. As the first finisher, he won 1 second prize of the National Science and Technology Progress Award, 3 first prizes at the provincial and ministerial levels, and the 14th Guanghua Engineering Science and Technology Award. He was awarded the title of Outstanding Communist Party Member of the Beijing Health System and Advanced Worker of Beijing, and was selected as a Beijing Scholar in 2019 and a member of the Academic Advisory Committee of the Chinese Academy of Medical Sciences. The precision diagnosis and treatment team for brain gliomas led by him was named the Beijing Worker Pioneer in 2022.